CPDD1543

CPDD1543 - Names and Identifiers

Name	N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide
Synonyms	CS-2808 AZD5069 AZD 5069 AZD-5069 CPDD1543 AZD 5069 ACT-281959 878385-84-3 N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide 1-Azetidinesulfonamide, N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R,2S)-2,3-dihydroxy-1-methylpropoxy]-4-pyrimidinyl]-
CAS	878385-84-3

CPDD1543 - Physico-chemical Properties

Molecular Formula	C18H22F2N4O5S2
Molar Mass	476.52
Density	1.56±0.1 g/cm3(Predicted)
Melting Point	149-152°C
Boling Point	680.5±65.0 °C(Predicted)
Solubility	DMSO
Appearance	Solid
Color	White to Off-White
pKa	4.56±0.20(Predicted)
Storage Condition	Hygroscopic, -20°C Freezer, Under inert atmosphere
Use	AZD-5069 is a potent and selective CXCR2 antagonist with the potential to inhibit neutrophil migration into the airways in patients with COPD. AZD-5069 was shown to inhibit binding of radiolabeled CXCL8 to human CXCR2 with a pIC50 value of 9.1. Furthermore, AZD5069 inhibited neutrophil chemotaxis, with a pA2 of approximately 9.6, and adhesion molecule expression, with a pA2 of 6.9, in response to CXCL1. AZD5069 was a slowly reversible antagonist of CXCR2 with effects of time and temperature evident on the pharmacology and binding kinetics. AZD-5069 is also potential useful for patient in inflammatory conditions.
Target	CXCR2

CPDD1543 - Reference

Reference

1: Uddin M, Watz H, Malmgren A, Pedersen F. NETopathic Inflammation in Chronic Obstructive Pulmonary Disease and Severe Asthma. Front Immunol. 2019 Feb 5;10:47. doi: 10.3389/fimmu.2019.00047. PMID: 30804927; PMCID: PMC6370641.
2: Cullberg M, Arfvidsson C, Larsson B, Malmgren A, Mitchell P, Wählby Hamrén U, Wray H. Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers. Drugs R D. 2018 Jun;18(2):149-159. doi: 10.1007/s40268-018-0236-x. PMID: 29856004; PMCID: PMC5995788.
3: De Soyza A, Pavord I, Elborn JS, Smith D, Wray H, Puu M, Larsson B, Stockley R. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. Eur Respir J. 2015 Oct;46(4):1021-32. doi: 10.1183/13993003.00148-2015. Epub 2015 Sep 4. PMID: 26341987.
4: Hickey MJ, Allen PH, Caffrey M, Hansen P, Kingston LP, Wilkinson DJ. Syntheses of a radiolabelled CXCR2 antagonist AZD5069 and its major human metabolite. J Labelled Comp Radiopharm. 2016 Sep;59(11):432-8. doi: 10.1002/jlcr.3429. Epub 2016 Jul 27. PMID: 27461061.
5: Watz H, Uddin M, Pedersen F, Kirsten A, Goldmann T, Stellmacher F, Groth E, Larsson B, Böttcher G, Malmgren A, Kraan M, Rabe KF. Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma. Pulm Pharmacol Ther. 2017 Aug;45:121-123. doi: 10.1016/j.pupt.2017.05.012. Epub 2017 May 23. PMID: 28549850.
6: Nicholls DJ, Wiley K, Dainty I, MacIntosh F, Phillips C, Gaw A, Mårdh CK. Pharmacological charact